Divis Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1jnihhcfhqm5rlctnf8cxynv.pdf

Key Takeaways


Custom Synthesis: The Growth Engine

Dr. Kiran S. Divi: "All I can say is I'm working with all the 4 innovators. Okay? And we're at various stages with them."

Generic Business: Volume Up, Price Down

Dr. Kiran S. Divi: "It's very hard to say when this will stabilize. Sometimes it takes one year, sometimes it takes 2 years. This has happened in the past in the year 2009-10, so it's repeating again, but prices will stabilize over time."

Capacity Expansion: Kakinada & Beyond


Cost Leadership & Technology Moat

Dr. Kiran S. Divi: "When Divi's started in the year 1994-95, okay, the price of Naproxen was at $100... Then you keep reinventing yourself. And today, the price is where the price is, in the sub-$40s."

Portfolio Mix & Strategy


Guidance & Commitments

CommitmentSpecificsTimeline
Kakinada Unit III startPhase-wise production activity to commenceH2 FY25 (Q2–Q3)
New CS facility operationalDedicated facility for long-term MNC supply agreementJanuary 2027
CS project commercial offtakeCustomer begins taking commercial quantities after validations and regulatory approvalsFrom 2027
Future generics contributionNew DMFs start contributing to revenueFY26/FY27
FY25 capexApproximately ₹1,500–₹1,600 cr (Kakinada Phase I balance + new CS facility)FY25
Double-digit growthEx-COVID business growth trajectoryGoing forward

Key Metrics

MetricQ4 FY24
Consolidated total income₹2,382 cr, vs ₹2,017 cr in Q4 FY23
Constant currency growth21%, vs negative 2% for FY24
Profit before tax₹713 cr
Profit after tax₹538 cr
Material consumption~39% of sales revenue
Product mix (Generics : Custom Synthesis)49% : 51%, vs 55% : 45% for FY24
Exports share~89% of revenue, vs ~87% for FY24
Nutraceutical business revenue₹188 cr, vs ₹724 cr for FY24
Forex impactLoss of ₹2 cr, vs gain of ₹30 cr for FY24
Cash on books₹3,980 cr as of March 31
Receivables₹2,156 cr as of March 31
Inventories₹3,184 cr as of March 31
Capital work in progress~₹778 cr as of March 31
Capitalized assets during the quarter₹201 cr, vs ₹402 cr for FY24
Custom Synthesis share shift~500 bps increase QoQ, from 46% in Q3 to 51% in Q4 (per an analyst's math)
Long-term supply agreement investment₹650 cr to ₹700 cr estimated, facility expected operational by January 2027
Kakinada Phase I capex spent~₹700 cr out of ₹1,500 cr total Phase I
FY25 capex guidance₹1,500 cr to ₹1,600 cr, comprising Phase I balance and the new project (per an analyst's math)
Post-patent generic opportunities identified7 molecules from FY25 over the next 5 years, with 1 or 2 coming off patent in FY25